acetazolamide

P2, N=66, Recruiting, Tanta University | Not yet recruiting --> Recruiting

Although the current therapeutic regimens for acute toxoplasmosis, most commonly a combination of pyrimethamine and sulfadiazine, are still considered the standard of care, they are associated with numerous drawbacks, such as bone marrow suppression, and hepatotoxicity. Histopathological examination of hepatic and renal tissue sections showed amelioration of parenchymal inflammation and scanty parasite. In conclusion, Acetazolamide demonstrated a significant promise as a therapeutic agent for combating acute murine toxoplasmosis with anti-inflammatory and antioxidant effects.

P2, N=66, Not yet recruiting, Tanta University

P4, N=303, Completed, University of Zurich | Recruiting --> Completed | Trial completion date: Dec 2025 --> Aug 2025 | Trial primary completion date: Dec 2025 --> Aug 2025

P1/2, N=11, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed

CAIX specificity was validated by a blocking study in which excess inhibitor reduced tumor uptake by 95 %. These findings identify [68Ga]Ga-14 as a highly promising CAIX-targeted PET tracer for sensitive detection of ccRCC, with potential for future theranostic applications.

By selecting the malignant tumor-associated marker CA9 and using acetazolamide (AAZ) as the targeting molecule, the bivalent biAAZ-Cy5.5 shows high specificity, high affinity, and low off-target binding...Oral coadministration of αVβ3-IRdye800CW and biAAZ-Cy5.5 in HT29 (CA9+, αVβ3+) and HCT116 (CA9-, αVβ3+) tumor-bearing mice demonstrated that biAAZ-Cy5.5 selectively targets the CA9-expressing tumors. The combination of an 800 nm integrin-targeting agent for high sensitivity with the 680 nm CA9-targeting agent for improved specificity highlights the utility of dual-channel imaging.

With K I = 35.0 nM against hCA IX and IC50 = 0.058 μM against VEGFR-2, as well as better selectivity than acetazolamide, compound 4a was shown to be the most powerful member...In hypoxic settings, it outperformed doxorubicin (IC50 = 3.65 vs. 9.42 μM), and it remained highly active in both normoxia and hypoxia...In silico ADMET predictions confirmed its drug-like profile, whereas molecular docking revealed advantageous interaction inside the ATP-binding site of VEGFR-2 and the zinc pocket of hCA IX. All things considered, compound 4a shows great promise as a dual-target inhibitor and potential chemosensitizer for the treatment of malignancies caused by hypoxia.

An in vivo biodistribution study was performed in SK-RC-52 xenograft-bearing mice, with and without carbonic anhydrase pre-blocking using acetazolamide...The study demonstrates the importance of 3D tumor models in evaluating alpha-particle cross-fire effects. Further ligand optimization is warranted to enhance tumor specificity and minimize off-target uptake.

P=N/A, N=64, Recruiting, Puerta de Hierro University Hospital | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Dec 2026 | Trial primary completion date: Feb 2025 --> May 2026

The patient subsequently developed hydrocephalus requiring a ventriculoperitoneal shunt, complicated by refractory ascites that resolved with acetazolamide therapy. Awareness of the potential disease spectrum through early molecular diagnosis, combined with a comprehensive immunologic evaluation, enabled individualized management via closer clinical monitoring and timely interventions to prevent and control neurological and infectious complications. This case highlights the phenotypic heterogeneity of PIK3CA pathogenic variants and the importance of early precision medicine in pediatric care.

P2, N=54, Completed, University of California, San Diego | Recruiting --> Completed